Last updated: September 8, 2026
Umeclidinium bromide/vilanterol trifenatate is the once-daily dual long-acting bronchodilator marketed in the United States as Anoro Ellipta by GSK. The product is approved for maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Its commercial position is being pressured by triple therapy, particularly GSK’s own fluticasone furoate/umeclidinium/vilanterol product Trelegy Ellipta, as well as competing long-acting muscarinic antagonist/long-acting beta2-agonist combinations.
Anoro remains a branded respiratory asset with no biosimilar pathway and limited near-term substitution risk from conventional generics. The main commercial risks are formulary competition, migration to triple therapy, inhaler-device complexity, and the eventual expiry of Orange Book-listed product and formulation patents. GSK does not publicly report Anoro revenue as a standalone line item, preventing a precise product-level revenue forecast from company filings (GSK plc, 2024).
What is umeclidinium bromide/vilanterol trifenatate?
Umeclidinium/vilanterol combines two once-daily bronchodilators:
| Component |
Pharmacology |
Role in COPD treatment |
| Umeclidinium bromide |
Long-acting muscarinic antagonist, or LAMA |
Relaxes airway smooth muscle by blocking muscarinic receptors |
| Vilanterol trifenatate |
Long-acting beta2-adrenergic agonist, or LABA |
Produces bronchodilation through beta2-receptor stimulation |
| Delivery system |
Ellipta dry-powder inhaler |
Delivers one inhalation once daily |
The U.S. product is Anoro Ellipta, approved by the FDA in December 2013 under NDA 203975. The indication is maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. It is not approved as a rescue inhaler and is not indicated for asthma (FDA, 2023).
The fixed-dose combination provides bronchodilation through two complementary mechanisms. It does not contain an inhaled corticosteroid, which differentiates it from Trelegy Ellipta.
What is the FDA regulatory status of Anoro Ellipta?
Anoro Ellipta is FDA-approved and commercially marketed in the United States. The product has also been approved in multiple international markets under GSK branding, although regulatory status and reimbursement differ by country.
| Regulatory item |
Status |
| U.S. brand |
Anoro Ellipta |
| Applicant |
GlaxoSmithKline |
| FDA application |
NDA 203975 |
| Active ingredients |
Umeclidinium bromide and vilanterol trifenatate |
| Dosage form |
Dry powder inhalation powder |
| Administration |
One oral inhalation once daily |
| Approved use |
Maintenance treatment of COPD |
| Rescue use |
Not approved |
| Asthma indication |
Not approved |
| Biologic status |
Not applicable |
Umeclidinium/vilanterol is a small-molecule combination product. A follow-on competitor would generally use the abbreviated new drug application pathway rather than the biosimilar pathway. The FDA has issued product-specific guidance for generic development of umeclidinium bromide/vilanterol inhalation powder, indicating that regulatory substitution will depend on demonstrating pharmaceutical equivalence, device performance, and bioequivalence through the applicable inhalation-product framework (FDA, 2020).
When did umeclidinium/vilanterol lose regulatory exclusivity?
The five-year new chemical entity exclusivity period associated with the original approval would have expired in 2018, assuming the relevant active ingredient qualified for NCE exclusivity. That regulatory exclusivity period is separate from patent protection and does not itself establish that a generic can launch.
The commercial protection profile now depends primarily on patents, FDA-listed patents, pediatric exclusivity, litigation stays, and the ability of an ANDA applicant to establish non-infringement, invalidity, or a licensed launch date.
A simplified U.S. exclusivity timeline is:
| Milestone |
Date or period |
| FDA approval of Anoro Ellipta |
December 2013 |
| Expected end of five-year NCE exclusivity |
2018 |
| Current protection basis |
Patents, device rights, formulation rights, and regulatory requirements |
| Generic pathway |
ANDA with therapeutic-equivalence and device-performance requirements |
| Biosimilar pathway |
Not applicable |
The absence of NCE exclusivity does not mean that generic entry is immediate. Inhaled combination products can face technical barriers involving device design, emitted dose, particle-size distribution, and product-specific bioequivalence.
What patents protect umeclidinium bromide/vilanterol?
Protection for Anoro is likely to arise from several patent categories rather than one composition-of-matter patent alone:
- Active pharmaceutical ingredient patents for umeclidinium and vilanterol.
- Fixed-dose combination patents.
- Dry-powder inhalation formulation patents.
- Ellipta inhaler and dose-delivery patents.
- Manufacturing and particle-engineering patents.
- Method-of-use patents for COPD treatment.
- Regulatory exclusivity associated with the original approval.
The most commercially important patents are those listed in the FDA Orange Book against the approved product and those that cover the inhaler or formulation in a way that is difficult to design around. The Orange Book must be checked for the current listing status, expiration dates, pediatric extensions, and any patent-use codes because listings can change through patent delisting, corrections, or expiration (FDA, 2024a).
Public company disclosures do not establish a single universally accepted “Anoro patent expiration date.” The relevant date depends on the specific patent, jurisdiction, pediatric extension, terminal disclaimer, and whether an ANDA applicant challenges the listed claims.
How strong is the Anoro patent estate?
The estate is technically stronger than a conventional oral small-molecule product because a generic developer must address both the active ingredients and the inhaler presentation. Its commercial strength is moderated by several factors:
- Umeclidinium and vilanterol are established small molecules.
- The product has a well-defined once-daily formulation.
- The Ellipta device may create design and regulatory barriers.
- Method-of-use claims may be narrower than composition or device claims.
- A generic company can challenge patents through Paragraph IV certifications.
- The FDA does not require a generic to copy every aspect of the brand’s device if the substitute satisfies applicable equivalence requirements.
The main vulnerability is that an ANDA applicant may attack only the patents that block approval or launch, rather than reproduce the entire branded patent estate.
Are there Paragraph IV challenges to Anoro?
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. If the brand holder sues within the statutory period after receiving notice, FDA approval may be stayed for up to 30 months, subject to court action and statutory exceptions.
No major publicly reported Anoro Paragraph IV settlement has established a widely recognized generic entry date comparable to the high-profile litigation histories of several oral medicines. The absence of a public settlement date does not eliminate future challenge risk. Inhaled combination products often generate litigation later than oral products because development requires specialized device and bioequivalence capabilities.
Potential generic launch scenarios are:
| Scenario |
Commercial effect |
| No ANDA approval |
Continued branded sales, subject to formulary erosion |
| ANDA approval without launch |
Patent or commercial barriers delay substitution |
| At-risk launch |
Immediate litigation and possible damages exposure |
| Licensed launch settlement |
Entry occurs on an agreed date, potentially before full patent expiry |
| First generic approval and launch |
Pharmacy substitution and price pressure accelerate |
What is the Orange Book status of Anoro Ellipta?
Anoro Ellipta is an FDA-listed prescription product. The Orange Book is the controlling public source for current U.S. patent listings, approved products, therapeutic-equivalence evaluations, and exclusivity information.
The Orange Book analysis should distinguish:
- Patents listed against Anoro’s NDA.
- Patents listed against the Ellipta inhaler or related products.
- Patents with method-of-use codes.
- Expired patents.
- Patents subject to pediatric extensions.
- Pending or approved generic applications.
- Therapeutic-equivalence codes for any approved substitutes.
An inhaled combination product can have limited direct pharmacy substitution even after a generic is approved. Payer formularies may require the generic to use a comparable device, offer a lower net price, or demonstrate equivalent adherence and handling.
How does Anoro compare with competing COPD products?
Anoro competes mainly in the once-daily LAMA/LABA segment and indirectly against triple therapy.
| Product |
Active ingredients |
Manufacturer |
Position |
| Anoro Ellipta |
Umeclidinium/vilanterol |
GSK |
Once-daily LAMA/LABA |
| Stiolto Respimat |
Tiotropium/olodaterol |
Boehringer Ingelheim |
Once-daily LAMA/LABA |
| Bevespi Aerosphere |
Glycopyrrolate/formoterol |
AstraZeneca |
LAMA/LABA |
| Utibron Neohaler |
Glycopyrrolate/indacaterol |
Novartis |
LAMA/LABA |
| Duaklir Pressair |
Aclidinium/formoterol |
AstraZeneca/associated partners |
LAMA/LABA |
| Trelegy Ellipta |
Fluticasone furoate/umeclidinium/vilanterol |
GSK |
Once-daily inhaled triple therapy |
Trelegy is strategically important because it contains both active ingredients in Anoro plus an inhaled corticosteroid. Patients with persistent symptoms, frequent exacerbations, or an appropriate eosinophilic profile may be moved to triple therapy. This creates internal cannibalization risk for Anoro while expanding the total value of GSK’s respiratory franchise.
What licensing deals affect umeclidinium/vilanterol?
The product originated from the long-acting respiratory collaboration between GSK and Theravance. The collaboration covered respiratory medicines based on long-acting muscarinic antagonist and beta2-agonist technologies.
Innoviva, which was separated from Theravance’s operating structure, has reported royalty economics associated with GSK respiratory products, including Anoro and Trelegy. These arrangements mean that product revenue and royalty revenue do not accrue exclusively to GSK. Contract terms, royalty rates, territories, and post-termination rights affect the economic value of the asset (Innoviva, 2024).
The commercial structure has three relevant layers:
- GSK controls the branded product, regulatory operations, and commercialization.
- Innoviva retains contractual economic interests in certain respiratory products.
- Third-party royalty transactions may transfer some economic rights without transferring the underlying marketing authorization or patent ownership.
What is the financial trajectory for Anoro?
GSK reports respiratory performance at portfolio and therapy-area levels, but public annual reports do not consistently provide a standalone Anoro revenue series. As a result, product-level revenue must be inferred from prescription trends, market share, disclosed portfolio growth, and royalty reports rather than taken directly from audited company revenue tables.
The financial trajectory has four phases:
2013 to 2017: launch and market formation
Anoro entered a growing COPD maintenance market with a once-daily LAMA/LABA product. Initial commercial growth depended on physician adoption, payer access, and competition from established tiotropium-based products.
2018 to 2021: class expansion
The LAMA/LABA market became more competitive as additional fixed-dose combinations reached the market. Anoro benefited from the broader movement toward dual bronchodilation but faced increased formulary negotiation.
2021 onward: triple-therapy pressure
Trelegy’s expansion created a stronger higher-value alternative for patients requiring escalation beyond dual bronchodilation. This increases the risk that Anoro functions as an earlier-line or intermediate product rather than the terminal branded therapy in the treatment pathway.
Mature-brand period
Future Anoro revenue is likely to depend on:
- U.S. formulary position.
- International reimbursement.
- Relative use of dual versus triple therapy.
- Generic entry timing.
- Ellipta device preference.
- GSK’s pricing and contracting strategy.
- Royalty obligations and geographic sales mix.
GSK’s broader respiratory portfolio remains financially material, but the company’s public disclosures do not isolate Anoro sufficiently to calculate a reliable standalone revenue growth rate, operating margin, or net present value (GSK plc, 2024).
What manufacturing and intellectual-property barriers affect generic entry?
Generic development requires more than reproducing the two active ingredients. Developers must address:
- Separate control of umeclidinium and vilanterol particle properties.
- Dose uniformity for a low-dose inhalation product.
- Aerodynamic particle-size distribution.
- Device resistance and emitted-dose consistency.
- Moisture control and product stability.
- Dose-counter and inhaler performance.
- Equivalence of delivered and fine-particle dose.
- Packaging and storage requirements.
The Ellipta device and inhalation formulation create a higher development burden than a conventional tablet. These barriers can delay entry even when composition-of-matter protection is weak or expired.
What generic entry risks exist for Anoro?
The highest-probability generic threat is a delayed, technically capable ANDA entrant rather than immediate multi-source substitution. Entry risk increases when:
- FDA product-specific guidance is mature.
- Listed patents approach expiration.
- A major inhalation-generic company completes device development.
- Payers create a preferred generic tier.
- The generic can avoid device patents through an alternative inhaler.
- A Paragraph IV settlement establishes an early entry date.
The price impact will depend on the number of approved suppliers. One authorized generic or first generic may produce modest initial erosion. Multiple generic suppliers typically create more substantial price compression and formulary displacement.
Does umeclidinium/vilanterol face biosimilar risk?
No. Umeclidinium bromide and vilanterol trifenatate are small molecules, not biologics. The relevant threat is generic substitution through the ANDA pathway. Biosimilar rules under the Public Health Service Act do not apply.
What patent litigation affects Anoro?
The most consequential potential litigation would involve:
- Paragraph IV challenges to Orange Book-listed patents.
- Claims covering the Ellipta inhaler.
- Fixed-dose formulation claims.
- Infringement disputes over dose delivery and particle engineering.
- Royalty disputes involving the GSK-Theravance/Innoviva arrangements.
No publicly established settlement has created a definitive, market-wide Anoro generic-entry date. Litigation monitoring should focus on FDA Paragraph IV notices, federal district court complaints, ANDA approval records, Orange Book changes, and GSK or Innoviva securities filings.
Key Takeaways
- Anoro Ellipta is GSK’s once-daily umeclidinium/vilanterol COPD product.
- FDA approval occurred in December 2013 under NDA 203975.
- The product has no biosimilar risk because it is a small-molecule combination.
- Its commercial protection depends on patents covering the formulation, inhaler, manufacturing process, and methods of use.
- Generic entry requires specialized inhalation-device and bioequivalence development.
- Trelegy Ellipta creates both portfolio leverage and internal cannibalization risk.
- GSK does not report a sufficiently detailed standalone Anoro revenue series for a precise product-level financial forecast.
- A definitive U.S. generic entry date cannot be inferred from approval timing alone.
- The FDA Orange Book remains the controlling source for current patent listings and therapeutic-equivalence status.
- Innoviva’s royalty arrangements affect the allocation of product economics between GSK and former Theravance interests.
FAQs
What is the brand name for umeclidinium bromide and vilanterol trifenatate?
The U.S. brand name is Anoro Ellipta, marketed by GSK.
Is Anoro Ellipta a steroid inhaler?
No. Anoro contains a LAMA and a LABA. It does not contain an inhaled corticosteroid.
Can Anoro be used for asthma?
Anoro is approved for maintenance treatment of COPD, not asthma. It is also not a rescue inhaler.
Is there a generic version of Anoro Ellipta?
A generic applicant may pursue approval through the ANDA pathway, but generic availability depends on FDA approval, patent status, litigation, and commercial launch. Product-specific inhaler requirements make development more complex than for an oral tablet.
Does Trelegy replace Anoro?
Trelegy can compete with or follow Anoro in treatment escalation, but it is not an automatic replacement. Trelegy adds fluticasone furoate and is intended for patients for whom triple therapy is clinically appropriate.
References
-
Food and Drug Administration. (2020). Product-specific guidance for umeclidinium bromide; vilanterol trifenatate inhalation powder. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023). Anoro Ellipta prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
GlaxoSmithKline plc. (2024). Annual report 2023. London, United Kingdom.
-
Innoviva, Inc. (2024). Annual report 2023. San Francisco, California.
